Standard BioTools Inc
NASDAQ:LAB

Watchlist Manager
Standard BioTools Inc Logo
Standard BioTools Inc
NASDAQ:LAB
Watchlist
Price: 1.27 USD 3.25% Market Closed
Market Cap: 482.4m USD

Wall Street
Price Targets

LAB Price Targets Summary
Standard BioTools Inc

Wall Street analysts forecast LAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LAB is 1.96 USD with a low forecast of 1.62 USD and a high forecast of 2.36 USD.

Lowest
Price Target
1.62 USD
27% Upside
Average
Price Target
1.96 USD
55% Upside
Highest
Price Target
2.36 USD
86% Upside
Standard BioTools Inc Competitors:
Price Targets
PPGN
PolyPeptide Group AG
0% Upside
CGEN
Compugen Ltd
295% Upside
WST
West Pharmaceutical Services Inc
32% Upside
PSNL
Personalis Inc
55% Upside
IQV
IQVIA Holdings Inc
15% Upside
DIVISLAB
Divi's Laboratories Ltd
4% Upside
BICO
BICO Group AB
75% Upside
688315
Novogene Co Ltd
7% Downside

Revenue
Forecast

Revenue Estimate
Standard BioTools Inc

For the last 8 years the compound annual growth rate for Standard BioTools Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

7%
Past Growth
6%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Standard BioTools Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
Standard BioTools Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-83%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LAB's stock price target?
Price Target
1.96 USD

According to Wall Street analysts, the average 1-year price target for LAB is 1.96 USD with a low forecast of 1.62 USD and a high forecast of 2.36 USD.

What is Standard BioTools Inc's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Standard BioTools Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

Back to Top